

The RapP-PhrP Quorum-Sensing System of *Bacillus subtilis* Strain NCIB3610 Affects Biofilm Formation through Multiple Targets, Due to an Atypical Signal-Insensitive Allele of RapP

Shira Omer Bendori, Shaul Pollak, Dorit Hizi,  Avigdor Eldar

Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel

The genome of *Bacillus subtilis* 168 encodes eight *rap-phr* quorum-sensing pairs. Rap proteins of all characterized Rap-Phr pairs inhibit the function of one or several important response regulators: ComA, Spo0F, or DegU. This inhibition is relieved upon binding of the peptide encoded by the cognate *phr* gene. *Bacillus subtilis* strain NCIB3610, the biofilm-proficient ancestor of strain 168, encodes, in addition, the *rapP-phrP* pair on the plasmid pBS32. RapP was shown to dephosphorylate Spo0F and to regulate biofilm formation, but unlike other Rap-Phr pairs, RapP does not interact with PhrP. In this work we extend the analysis of the RapP pathway by reexamining its transcriptional regulation, its effect on downstream targets, and its interaction with PhrP. At the transcriptional level, we show that *rapP* and *phrP* regulation is similar to that of other *rap-phr* pairs. We further find that RapP has an Spo0F-independent negative effect on biofilm-related genes, which is mediated by the response regulator ComA. Finally, we find that the insensitivity of RapP to PhrP is due to a substitution of a highly conserved residue in the peptide binding domain of the *rapP* allele of strain NCIB3610. Reversing this substitution to the consensus amino acid restores the PhrP dependence of RapP activity and eliminates the effects of the *rapP-phrP* locus on ComA activity and biofilm formation. Taken together, our results suggest that RapP strongly represses biofilm formation through multiple targets and that PhrP does not counteract RapP due to a rare mutation in *rapP*.

The behavior of bacterial communities is often regulated by quorum-sensing (QS) signaling pathways. In these pathways, a secreted molecular signal accumulates in the environment and activates a cognate receptor at sufficiently high concentrations. Gram-positive bacteria frequently utilize peptides as QS signals (1–3), thereby eliciting a variety of behaviors, including the secretion of various molecules (e.g., enzymes, antibiotics, surfactants, and exopolysaccharides [4]), the initiation of developmental processes (such as sporulation and biofilm formation), and horizontal gene transfer through transformation or conjugation (5–7).

Members of the Rap-Phr family of QS systems in the Gram-positive model *Bacillus subtilis* are involved in the regulation of competence, sporulation, and biofilm formation. The chromosome of strain *B. subtilis* 168 encodes eight full receptor signal systems and three orphan receptors from this family (6, 8). In each of the full systems, the *phr* gene encodes a prepeptide, which is secreted through the major secretory system and then further processed outside the cell, resulting in the formation of a mature penta- or hexapeptide signal (9). The mature peptide is transported into the cell by the oligopeptide-permease (Opp) complex, where it interacts with its Rap targets within the cytoplasm (10). All characterized Rap proteins contain two domains (10–12), a tricopeptide repeat (TPR) domain that interacts with the signaling peptide and a second domain that functions either as a phosphatase or as a contact-dependent inhibitor of a response regulator. Rap proteins exert their activity only in the peptide-free form as binding of the signaling peptide leads to the inactivation of the Rap protein and to subsequent derepression of the response regulator.

Three response regulators have been characterized as targets of Rap proteins in the so-called laboratory or domesticated strain 168 and include Spo0F, ComA, and DegU. Spo0F, a component of the *spo0A* activation phosphorelay, is repressed by RapA, RapB,

RapE, RapH, RapI, and RapJ. The *spo0A* pathway regulates multiple processes in the cell; most notably, sporulation is activated at high Spo0A phosphorylation levels, while biofilm formation requires lower levels of phosphorylation (13, 14). Spo0A, through regulation of the transcriptional regulator AbrB and the sigma factor σ^H , also controls the transcription of many of the *phr* genes from an internal promoter within the *rap-phr* operon (15). The QS response regulator ComA was shown to be repressed by RapC, RapD, RapF, RapH, and RapK (16, 17). ComA is an activator of many of the Rap proteins, thereby forming a complex regulatory network between the various QS pathways (18). Finally, RapG represses phosphorylated DegU (DegU~P) (19), whose main functions are to promote the secretion of multiple enzymes and repress social motility (20). Recently, it was hypothesized that a plasmid-borne Rap (specifically, Rap carried by plasmid pLS20 [Rap_{pLS20}]) may also interact directly with an Xre-type plasmid-borne repressor (21).

The laboratory strain, *B. subtilis* 168, and its derivatives (in-

Received 7 October 2014 Accepted 17 November 2014

Accepted manuscript posted online 24 November 2014

Citation Omer Bendori S, Pollak S, Hizi D, Eldar A. 2015. The RapP-PhrP quorum-sensing system of *Bacillus subtilis* strain NCIB3610 affects biofilm formation through multiple targets, due to an atypical signal-insensitive allele of RapP. *J Bacteriol* 197:592–602. doi:10.1128/JB.02382-14.

Editor: G. A. O'Toole

Address correspondence to Avigdor Eldar, avigdor@gmail.com.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JB.02382-14>.

Copyright © 2015, American Society for Microbiology. All Rights Reserved. doi:10.1128/JB.02382-14




FIG 1 The proposed RapP interaction network. The scheme illustrates the RapP network in *B. subtilis* 3610 based on previous results (black arrows), including the additional interactions (gray arrows) which are proposed on the basis of results reported in this work. RapP (red) is a repressor of Spo0F activity and, directly or indirectly, represses ComA in an Spo0F-independent manner. RapP is repressed by the mature PhrP peptide (A)DRAAT, produced by secretion and subsequent cleavage of PhrP (the three-colored rectangle represents a signal peptide, an extracellularly cleaved prepeptide, and a mature peptide). ComA is activated by the ComX~P QS system (blue) and directly controls the transcription of several operons, including the *srfA* operon. The exopolysaccharide (*eps*) operon is indirectly controlled by ComA. Spo0A, the master regulator of sporulation and biofilm formation, indirectly regulates the expression of the *eps* operon and of the *phrP* gene. Spo0F is part of the phosphorylation that activates Spo0A and is a known target of many Rap proteins. *rapP* of strain NCIB3610 encodes an atypical substitution that prevents its repression by the PhrP signaling peptide.

cluding strain PY79 used in this work) have undergone multiple genetic changes during domestication from their ancestral strain, *B. subtilis* NCIB3610 (denoted 3610 in this work). These changes led to the loss of multiple phenotypes, such as the ability to produce an extracellular matrix and the surfactant surfactin, both necessary for biofilm formation (22). The lab strain also shows an increased frequency of genetic competence compared to its ancestor, a feature that facilitates its genetic manipulation in the laboratory (23). Currently, research dealing with biofilm formation in *Bacillus subtilis* has therefore shifted away from the domesticated strains such as 168 and its derivatives and is primarily focused on strain 3610, which is considered a more suitable representative of wild strains that display social phenotypes (24). It should be noted that in terms of their biofilm-forming properties, there is a relatively small number of mutations that distinguish the undomesticated strain 3610 and the lab strains (25). These include mutations in enzymes necessary for the production of exopolysaccharides and surfactin, as well as mutations in various regulatory proteins.

An additional major difference between the lab strains and strain 3610 is that strain 3610 possess an 80-kb plasmid, termed pBS32, which is absent from the lab strains (26). This plasmid is not found in other isolates of *B. subtilis* subsp. *subtilis* (27), but a highly homologous plasmid, pLS32, which is found in a more distant strain of *B. subtilis* subsp. *natto*, has been analyzed and sequenced (28). Notably, pBS32 has been shown to carry an additional *rap-phr* cassette, termed *rapP-phrP*, and RapP was specifically shown to contribute to the difference in biofilm-forming capabilities between strains 3610 and 168 (25) (Fig. 1). Recently, it was shown that RapP functions as a phosphatase of *spo0F* *in vitro*. Furthermore, it was demonstrated *in vivo* that a *rapP* deletion affects the expression of direct targets of Spo0A. RapP was also shown to inhibit the transcription of the *eps* and *srfA* operons, whose gene products are responsible for the production of exopolysaccharides (*eps*) (29, 30) and the surfactant surfactin (*srfA*).

Both of these operons are regulated by numerous other regulators, and the experiments did not rule out the possibility that RapP affects these operons through other regulators. Finally, it was found that, unlike all other characterized Rap-Phr pairs, the effect of RapP on gene expression is not suppressed by the expression of its adjoining *phrP* signaling gene or by external addition of the presumed PhrP signaling peptides to the medium. It was observed, however, that weak suppression of RapP was achieved with the addition of the PhrH signaling peptide to the medium (29). RapP is therefore unique among all Rap-Phr pairs in that it appears not to interact with its cognate PhrP peptide. It is therefore unclear what the function of *phrP* is and what features of the RapP system can explain this difference between *rapP-phrP* and other *rap-phr* pairs.

Here, we report the results of genetic analysis that examined three layers of regulation of the RapP pathway: (i) the transcriptional regulation of pathway, (ii) the effect on downstream targets, and (iii) RapP interaction with PhrP. We find that the transcriptional regulation of *rapP-phrP* is reminiscent of the transcriptional organization of other *rap-phr* pairs (31) and that *rapP* has an additional target beside Spo0F, which regulates the repression of *srfA* and *eps* in a ComA-dependent manner. Finally, we find that a highly conserved amino acid of the Rap TPR domain has been replaced in the *rapP* allele of strain 3610 (*rapP*³⁶¹⁰). Reconstitution of the consensus amino acid in RapP restored the interaction between PhrP and RapP and eliminated the effects of RapP on biofilm formation.

MATERIALS AND METHODS

Growth media. Routine growth experiments were performed in Luria-Bertani (LB) broth containing 1% tryptone (Difco), 0.5% yeast extract (Difco), and 0.5% NaCl. Most gene expression measurements were done using Spizizen minimal medium (SMM) containing 2 g liter⁻¹ (NH₄)₂SO₄, 14 g liter⁻¹ K₂HPO₄, 6 g liter⁻¹ KH₂PO₄, 1 g liter⁻¹ disodium citrate, and 0.2 g liter⁻¹ MgSO₄·7H₂O supplemented with 125 mg liter⁻¹ MgCl₂·6H₂O, 5.5 mg liter⁻¹ CaCl₂, 13.5 mg liter⁻¹ FeCl₂·6H₂O, 1 mg liter⁻¹ MnCl₂·4H₂O, 1.7 mg liter⁻¹ ZnCl₂, 0.43 mg liter⁻¹ CuCl₂·4H₂O, 0.6 mg liter⁻¹ CoCl₂·6H₂O, 0.6 mg liter⁻¹ Na₂MoO₄·2H₂O, and 0.5% glucose. Biofilm growth was done on MSgg medium plates; MSgg medium contains 100 mM morpholinepropanesulfonic acid (MOPS) (pH 7), 0.5% glycerol, 0.5% glutamate, 5 mM potassium phosphate (pH 7), 50 μg ml⁻¹ tryptophan, 50 μg ml⁻¹ phenylalanine, 2 mM MgCl₂, 700 μM CaCl₂, 50 μM FeCl₃, 50 μM MnCl₂, 2 μM thiamine, and 1 μM ZnCl₂ (22). Media were solidified using 1.5% agar (Difco). The following antibiotics were used (concentrations): macrolides-lincosamides-streptogramin B (mls; 1 μg ml⁻¹ erythromycin, 25 μg ml⁻¹ lincomycin), spectinomycin (Sp; 100 μg ml⁻¹), chloramphenicol (Cm; 5 μg ml⁻¹), and kanamycin (Kan; 15 μg ml⁻¹). Isopropyl-β-D-thiogalactopyranoside (IPTG; Sigma) was added to the medium when appropriate, at the concentrations indicated in the text and figure legends.

Strain and mutant construction. All of the strains used in this study are listed in Table 1. Deletion of *comA* from the PY79 chromosome and its replacement with a chloramphenicol resistance cassette were performed through the long flanking homology PCR method (32) using the primers *comA*-P1, *comA*-P2, *comA*-P3, and *comA*-P4.

To generate inducible *zba88::(P_{hs}-rapP)* and *zba88::(P_{hs}-phrP)* constructs (where *P_{hs}* is the hyperspank promoter), a PCR product containing the relevant open reading frame (ORF) was amplified using the *hsRapP*-F/*hsRapP*-R and *hsPhrP*-F/*hsPhrP*-R primer pairs. The PCR products were digested with NheI and SphI and ligated downstream of the hyperspank promoter of the pDR111 vector containing spectinomycin resistance (33).

The construction of transcriptional fusions to *yfp* was performed by

TABLE 1 Strain list

Genetic background ^a	Strain name	Genotype or description	Source, reference, or construction method ^b
3610	AES1109	<i>B. subtilis</i> NCIB3610 wild type	<i>Bacillus</i> genetic stock center
PY79	AES101	<i>B. subtilis</i> PY79 wild type	<i>Bacillus</i> genetic stock center
PY79	AES1419	<i>amyE::</i> (<i>P_{rapA}</i> -3×YFP Sp)	This study
PY79	AES1502	<i>amyE::</i> (<i>P_{rapA}</i> -3×YFP Sp) Δ <i>comA::</i> Cm	AES1403→AES1419
PY79	AES1403	Δ <i>comA::</i> Cm	This study
PY79	AES1444	<i>amyE::</i> (<i>P_{rapA}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km)	AES1370→AES1419
PY79	AES1503	<i>amyE::</i> (<i>P_{rapA}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km) Δ <i>comA::</i> Cm	AES1370→AES1502
PY79	AES1334	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp)	This study
PY79	AES1379	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km)	AES1370→AES1334
PY79	BS225	Δ <i>spo0A::</i> Km	Kind gift of the Ben-Yehuda lab
PY79	AES1472	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) Δ <i>spo0A::</i> Km	BS225→AES1334
PY79	AES1874	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km) Δ <i>spo0A::</i> Km	AES1370→AES1472
PY79	DS1993	Δ <i>degU::</i> mls	Kind gift of the Kearns lab
PY79	AES1875	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) Δ <i>degU::</i> mls	AES1334→DS1993
PY79	AES1606	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km) Δ <i>degU::</i> mls	AES1370→1875
PY79	AES1876	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) Δ <i>degU::</i> mls Δ <i>spo0A::</i> Km	BS225→AES1875
PY79	AES1877	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km) Δ <i>degU::</i> mls Δ <i>spo0A::</i> Km	AES1370→AES1876
3610	AES1401	<i>amyE::</i> (<i>P_{rapP}</i> -3×YFP Sp)	This study
PY79	AES1377	<i>amyE::</i> (<i>P_{rapP}</i> -3×YFP Sp)	This study
3610	AES1411	<i>amyE::</i> (<i>P_{rapP}</i> -3×YFP Sp)	This study
3610	AES1452	<i>amyE::</i> (<i>P_{rapP}</i> -3×YFP Sp) Δ <i>comA::</i> Cm	AES1403→AES1401
3610	AES1714	<i>amyE::</i> (<i>P_{phrP}</i> -3×YFP Sp) Δ <i>spo0A::</i> Km	BS225→AES1411
PY79	RL620	Δ <i>abrB::</i> mls	50
3610	AES1668	<i>amyE::</i> (<i>P_{phrP}</i> -3×YFP Sp) Δ <i>abrB::</i> mls	RL60→AES1411
PY79	RL2201	Δ <i>spo0H::</i> Km	50
3610	AES1413	<i>amyE::</i> (<i>P_{phrP}</i> -3×YFP Sp) Δ <i>spo0H::</i> Km	RL2201→AES1411
PY79	AES1819	<i>amyE::</i> (<i>P_{eps}</i> -3×YFP Sp)	This study
PY79	AES1820	<i>sacA::</i> (<i>P_{rapP}</i> - <i>rapP</i> - <i>phrP</i> Cm) <i>amyE::</i> (<i>P_{eps}</i> -3×YFP Sp)	AES913→AES1819
PY79	AES1827	<i>amyE::</i> (<i>P_{eps}</i> -3×YFP Sp) Δ <i>comA::</i> Cm	AES1403→AES1819
PY79	AES1828	<i>amyE::</i> (<i>P_{eps}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km) Δ <i>comA::</i> Cm	AES1370→AES1827
3610	DS2569	pBS32 plasmid cured	Kind gift of the Kearns lab
3610	AES1821	pBS32 plasmid cured; <i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp)	AES1334→DS2569
3610		pBS32 plasmid cured; <i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km)	AES1370→AES1821
3610	AES1836	pBS32 plasmid cured; <i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) Δ <i>spo0A::</i> Km	BS225→AES1821
3610	AES1837	pBS32 plasmid cured; <i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) Δ <i>spo0A::</i> Km <i>zba88::</i> (<i>P_{hs}</i> - <i>rapP</i> Sp Cm Km)	AES1370→AES1836
3610	AES1605	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp); plasmid cured	AES1334→DS2569
3610	AES1707	Δ <i>rapP</i> - <i>phrP</i> <i>sacA::</i> (<i>P_{rapP}</i> - <i>rapP</i> ^{N236T} - <i>phrP</i> Cm)	AES1656→DS8796
PY79	AES1709	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>phrP</i> Sp Cm Km) <i>sacA::</i> (<i>P_{rapP}</i> - <i>rapP</i> ^{N236T} Cm)	AEC735→AES1477
PY79	AES1478	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>phrP</i> Sp Cm Km) <i>sacA::</i> (<i>P_{rapP}</i> - <i>rapP</i> - <i>phrP</i> Cm)	AES913→AES1477
PY79	AES1477	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>zba88::</i> (<i>P_{hs}</i> - <i>phrP</i> Sp Cm Km)	This study
PY79	AES1678	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>sacA::</i> (<i>P_{rapP}</i> - <i>rapP</i> ^{N236T} Cm)	AES1656→AES1337
PY79	AES1380	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>sacA::</i> (<i>P_{rapP}</i> - <i>rapP</i> - <i>phrP</i> Cm)	AES913→AES1337
3610	AES1873	Δ <i>rapP</i> - <i>phrP</i> <i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp) <i>sacA::</i> (<i>P_{rapP}</i> - <i>rapP</i> ^{N236T} Cm)	AES1337→AES1707
3610	DS8796	Δ <i>rapP</i> - <i>phrP</i>	29
3610	AES1336	<i>amyE::</i> (<i>P_{srf}</i> -3×YFP Sp)	This study
PY79	AES1418	<i>amyE::</i> (<i>P_{pel}</i> -3×YFP Sp)	This study

^a Description of strains and their construction methods. Further details on the construction of relevant plasmids is given in Materials and Methods.

^b An arrow indicates transformation of genomic DNA. The recipient strain is on the right. Plasmid construction is described in Materials and Methods.

PCR amplification of the relevant promoter using 3610 genomic DNA as a template. To generate the promoter fusions, PCR fragments were amplified using the following primer pairs: *P_{srf}*, Psrf-F/Psrf-R; *P_{eps}*, Peps-F/Peps-R; *P_{rapP}*, PrapP-F/PrapP-R; *P_{phrP}*, PphrP-F/PphrP-R; *P_{rapA}*, PrapA-F/PrapA-R; *P_{slrA}*, PslrA-F/PslrA-R; *P_{slrR}*, PslrR-F/PslrR; *P_{sinI}*, PsinI-F/PsinI-R (Table 2). After fragments were digested with the appropriate enzymes (purchased from New England BioLabs), they were ligated to the plasmid pDL30-3×YFP containing three copies of the yellow fluorescent protein (YFP) (34). The resulting constructs were integrated into the *amyE* site on the chromosome using spectinomycin resistance for selection.

Construction of *sacA::*(*P_{rapP}* *rapP*-*phrP* Cm) and *sacA::*(*P_{rapP}* *rapP*

Cm) was performed by PCR amplification of the annotated *rapP* and *phrP* genes or of *rapP* together with 400 bp upstream of *rapP* using the primer pair rapP-phrP-F/rapP-phrP-R or rapP-phrP-F/rapP-R, respectively. The PCR products were digested with EcoRV and SphI and ligated into the *sacA* locus of pSac-cm.

A *rapP* gene encoding the T-to-N amino acid change at position 236 (*rapP*^{T236N}) was constructed by site-directed mutagenesis. The 5' phosphorylated primer pair rapP-phrP-TtoN-F/rapP-phrP-TtoN-R, in which the primers are adjoining but with reversed alignments, was designed to amplify the entire *sacA::*(*P_{rapP}* *rapP* Cm)-containing vector and change the codon ACC (threonine) to AAC (asparagine). The PCR product was used for self-ligation and transformed to PY79 cells.

TABLE 2 Primer list

Name ^a	Sequence ^b	Enzyme
PrapP-F	AAGTGAATTCCTTCATCCGGAGACTATTTAT	EcoRI
PrapP-R	GTGGGGATCCTCAAATACCTCCTTTTCTTT	BamHI
PphrP-F	AAGTGAATTCGCTTTAGAAACAGCTGAAA	EcoRI
PphrP-R	GTGGGGATCCATGAAGCGCTAGATACTCCA	BamHI
PrapA-F	CGACCGAATTCAAAACCTTACAGAAGGCTT	EcoRI
PrapA-R	GCAGAGCTAGCTGAATTACCCGAGATATGTC	NheI
Peps-F	GTGCGGAATTCGTCGTTATTTTCGTTTATTAT	EcoRI
Peps-R	AGTTGGCTAGCTCATGTATTTCATAGCCTTCA	NheI
Psrf-F	ATGGGGAAATTCGTTGTAAGACGCTC	EcoRI
Psrf-R	AGGTGGCTAGCTTTATAAGCAGTGAACAT	NheI
rapP-phrP-F	AGGAGGATATCTTCATCCGGAGACTATTTATGAACAA	EcoRV
rapP-phrP-R	CTCCTGCATGCTTAGGTGGTAGCACCATTCTTGCA	SphI
rapP-R	ATGAAGCATGCTTACATTTTTTCATTAAATG	SphI
hsRapP-F	ATCCAGCTAGCAAAGAAAAGGAGGTATTTGATTG	NheI
hsRapP-R	ATCCGGCATGCCAAGAGCGCTAAACAAATTTG	SphI
hsPhrP-F	ATCCAGCTAGCAAATTCAAAGGGGAAACATTTAAATG	NheI
hsPhrP-R	ATCCGGCATGCTTAAAGTTGCTGCTCTATCTG	SphI
rapP-phrP-NtoT-F	[phos]AGCTCATTTTAAACGTGGGATTA	
rapP-phrP-NtoT-R	[phos]GAACCAATTAATGTTGCTCCTC	
comA-P1	AAGTTGACCCGGACTGGAAT	
comA-P2	TTTTCTAATGTCACTAACCTGCCAACTGTTGCTCGGTTTCAG	
comA-P3	AGTAATCCGCCCCGACGGTATAGCGGTCCATTGAATACAGC	
comA-P4	GGTAGCCCGGTGATGTTTAC	

^a See Materials and Methods for descriptions. Primer rapP-phrP-NtoT-F contains the mutated base necessary for creating the T236N substitution by performing a C-to-A mutation. This base is shown in boldface in the sequence. F, forward; R, reverse.

^b The restriction enzyme recognition sequences are underlined. [phos] indicates the 5' phosphorylated primer.

All of the mutations and constructs were transferred to PY79 cells by transformation (35) and to 3610 by phage SPP1-mediated generalized transduction (36). Integration of *amyE* integration plasmids into the *zba88::amyE* Ω Cm Kan strain was done in two steps. First, the plasmid was integrated into a PY79 strain carrying the *zba88* construct and screened for an Amy⁺ phenotype. A genomic prep of the resulting strain was then inserted into other strains with selection for either Kan or Cm, depending on the genetic background of the integrated genome.

Biofilm formation assay. Bacteria were grown overnight in MSgg broth, diluted 1:100, and grown to an optical density at 600 nm (OD₆₀₀) of ~1.0. Five microliters of the culture was plated on MSgg agar, and the plates were incubated at 30°C for 72 h.

Peptide synthesis. A synthetic PhrP 5-mer peptide (NH₂-DRAAT-COOH), PhrP 6-mer peptide (NH₂-ADRAAT-COOH), and PhrH 6-mer peptide (NH₂-TDRNTT-COOH) were purchased from GL Biochem (Shanghai, China) at >98% purity. Aliquots (10 mM) were prepared by resuspension of the lyophilized peptides in H₂O and stored at -20°C.

Gene expression analysis. Flow cytometry was used to quantify gene expression at the single-cell level using a Beckman-Coulter Gallios system with a 488-nm laser. The cells were grown in SMM to an OD₆₀₀ of ~0.1, diluted by a factor of 10⁶ in fresh SMM, and grown for about 20 h to the beginning of the exponential phase. Samples were taken at several time points, and the OD and YFP levels were measured. A minimum of 20,000 cells were analyzed for each sample. The results are presented as the mean YFP level of the population for a specific OD (calculated by interpolation from actual OD measurements) and the standard error of the mean. The results represent the average of at least three independent experiments. YFP levels are measured as a ratio between the measured strain and the autofluorescence of a wild-type strain. Autofluorescence of the wild type did not change by more than 5% at different stages of growth in SMM.

RESULTS

The transcriptional regulation of *rapP-phrP* in 3610 is similar to the regulation of other *rap-phr* pairs. We first examined

whether the transcriptional regulation of the *rapP-phrP* operon reflects the unique independence of RapP from PhrP or whether it is similar to other *rap-phr* pairs. To this end, we cloned the regions immediately upstream of the *rapP* and *phrP* ORFs into the 3×YFP reporter plasmid and integrated each of the reporters separately into the *amyE* locus of strain 3610. The expression of each promoter was monitored in several genetic backgrounds (Fig. 2). Expression of *P_{rapP-3}×YFP* showed only a moderate increase as the cells approached the stationary phase (Fig. 2A). *P_{rapP-3}×YFP* expression was slightly lower in a *comA* deletion background, suggesting a possible weak regulation by ComA. The *phrP* internal promoter reporter (*P_{phrP-3}×YFP*) doubled its activity during transition from early log to stationary phase (Fig. 2B). Promoter activity was markedly reduced in a Δ *spo0A* background (Fig. 2B). In order to gain further insight into the activation of *P_{phrP-3}×YFP* by Spo0A, the expression of the reporter was monitored in strains carrying null mutations in *sigH* or *abrB*. As shown in Fig. 2B, the strain carrying a *sigH* deletion exhibited reduced expression while the strain carrying an *abrB* deletion showed an increase in expression levels.

The results shown in Fig. 2 indicate that the transcriptional regulation of the *rapP-phrP* locus resembles the transcriptional regulation of other *rap-phr* loci even though its activity does not depend on an interaction with PhrP.

RapP regulates the expression of *comA*-dependent genes in an *spo0F*-independent pathway. It was previously shown that RapP strongly represses the expression of the *srfA* promoter in strain 3610 (29). Since *srfA* expression is modulated by multiple QS systems whose functions are not well characterized in strain 3610, we examined whether this repression is conserved when RapP is expressed in the genetic background of the lab strain PY79




FIG 2 Transcriptional regulation of *rapP* and *phrP* promoters. Cells were grown in SMM, and their YFP fluorescence was measured as a function of time as described in Materials and Methods. Time zero is defined as the time when the OD equals 1.5. (A) YFP levels of wild-type 3610 (AES1401, open circle) and the $\Delta comA$ 3610 (AES1452, filled circle) strains carrying a P_{rapP} -3 \times YFP reporter. (B) YFP levels in the wild-type strain 3610 background carrying a P_{phrP} -3 \times YFP reporter with the following genetic modifications: wild type (AES1411, open circles), $\Delta spo0A$ (AES1714, filled circles), $\Delta abrB$ (AES1668, filled squares), and $\Delta sigH$ (AES1413, open squares). Expression levels in this and the following figures are given as the ratio between the mean expression levels of the designated genotype to the autofluorescence of the wild-type PY79. We find autofluorescence to be very stable when cells are grown in minimal medium. Error bars represent the standard error of the mean for at least three independent experiments.

in which QS is well characterized. The use of strain PY79 also allowed us to ignore interactions of RapP with plasmid-borne genes (as described with other Rap proteins [21, 37]). In addition, the activity could be assessed without the indirect effects that surfactin may have on gene expression (38). To this end, *rapP* together with its promoter was cloned into the *sacA* locus of PY79. The *rapP* gene was also cloned together with its native ribosomal binding site downstream of the IPTG-inducible hyperspank promoter (P_{hs}) and subsequently integrated into an ectopic *amyE* locus positioned at 33° on the bacterial chromosome, as previously described (34, 39, 40). To monitor *srfA* expression, we cloned the previously characterized (41) 560-bp promoter of the *srfA* operon in front of the 3 \times YFP reporter, which was integrated into the native *amyE* locus. The resulting P_{srfA} -3 \times YFP reporter was then introduced into three strains, parent PY79 and the P_{hs} -*rapP* and P_{rapP} -*rapP* strain backgrounds as described in Materials and Methods. Expression of *rapP* in strain PY79, either from its native promoter or from the hyperspank promoter supplemented with 10 μ M IPTG, led to an \sim 10-fold reduction in YFP levels (Fig. 3B; see also Fig. 5B).

While *srfA* transcription is strongly activated by ComA, there are several other transcriptional regulators that directly regulate this operon, and an interaction between RapP and any of these regulators may lead to the same observed effect. If RapP exerts its effect on the *srfA* promoter through the repression of ComA activity, we would expect to see other genes in the ComA regulon respond in a similar fashion. To check this hypothesis, we cloned the promoters of *pel* and *rapA*, two known direct targets of ComA (4), into the 3 \times YFP vector. We compared the expression of the *srfA*, *pel*, and *rapA* reporters in both the parental PY79 background and the inducible P_{hs} -*rapP* background. The expression of all three genes was markedly reduced when expression of *rapP* was induced compared to the wild-type level (Fig. 3A and B; see also

Fig. S1 in the supplemental material). Unlike the *srfA* promoter, the promoter of *rapA* has a strong residual expression in a *comA* null mutant background. We found that RapP had no effect on this residual expression (Fig. 3A), demonstrating the epistatic interaction between RapP and ComA. These results suggest that RapP inhibits ComA activity, either directly or indirectly.

ComA activity is modulated in strain PY79 by Spo0A activity through Spo0A regulation of *phrC* and other *phr* genes (15). If RapP repression of ComA activity is dependent on RapP-catalyzed dephosphorylation of Spo0F, we would expect that RapP would have no effect on ComA activity in a *spo0A* or *spo0F* null mutant. To explore this hypothesis, the P_{srfA} -3 \times YFP reporter was introduced into strains carrying either the $\Delta spo0A$ or $\Delta spo0A$ P_{hs} -*rapP* genetic background, and YFP levels were compared. We found that in a $\Delta spo0A$ mutant, P_{srfA} -3 \times YFP expression was reduced 4-fold compared to that of the parental PY79 strain. YFP levels were further reduced 9-fold when RapP was induced in the *spo0A* null background (Fig. 3B). We further verified that RapP inhibition of the P_{srfA} -3 \times YFP reporter was independent of *degU* or of the combination of *degU* and *spo0A* (Fig. 3B). These results clearly indicated that RapP has additional targets beyond Spo0F which mediate its inhibition of ComA activity.

Since strain 3610 differs from strain PY79 in multiple loci, the question arose as to whether the *spo0A*-independent effect of RapP on *srfA* activity could also be observed when these other mutations are taken into account. We therefore examined the epistatic interaction between *spo0A* and *rapP* in a derivative of strain 3610 that was cured of the pBS32 plasmid (strain DS2569). The same pattern of interactions was observed; namely, *srfA* expression in an P_{hs} -*rapP* $\Delta spo0A$ background was significantly lower than expression in an *spo0A* null background (Fig. 3C).

The *eps* operon is positively regulated by ComA, and this regulation is epistatic to *rapP*. It was previously shown that RapP




FIG 3 RapP effect on ComA reporters in various genetic backgrounds. Promoter activity was measured in each genotype with (+) or without (-) a $P_{hs-rapP}$ construct. (A) Shown are the YFP expression levels of four strains carrying the P_{rapA} -3×YFP reporter in the following backgrounds: wild-type PY79 (AES1419), $P_{hs-rapP}$ (AES1444), $\Delta comA$ (AES1502), and $P_{hs-rapP} \Delta comA$ (AES1503). (B) YFP levels were measured in a PY79 P_{srfA} -3×YFP background without (-) and with (+) an IPTG-inducible $rapP$ construct. The following genetic backgrounds are used: wild-type PY79 (AES1334), $P_{hs-rapP}$ (AES1379), $\Delta spo0A$ (AES1472), $\Delta spo0A P_{hs-rapP}$ (AES1874), $\Delta degU$ (AES1875), $\Delta degU P_{hs-rapP}$ (AES1606), $\Delta degU \Delta spo0A$ (AES1876), and $\Delta degU \Delta spo0A P_{hs-rapP}$ (AES1877). (C) The experiment is the same as that described for panel B but in a background of a plasmid-free derivative of strain 3610. The following genotypes were used: the wild-type plasmid-free strain (strain AES1605), $P_{hs-rapP}$ strain (AES2472), $\Delta spo0A$ strain (AES2436), and $\Delta spo0A P_{hs-rapP}$ strain (AES2437). All measurements were performed at an OD_{600} of 1.5. All genetic backgrounds with the $P_{hs-rapP}$ construct were induced with 10 μM IPTG. In this and the following figures, the difference between all pairs marked with an asterisk are statistically significant (t test, $P < 0.05$).

strongly affects the biofilm phenotype of *B. subtilis* 3610 (25, 29). In this regard it was reported that RapP regulates the expression of the *eps* operon, which encodes all structural genes needed for the production and secretion of the exopolysaccharide component of the biofilm matrix (29, 30). To examine this regulation further, we constructed a P_{eps} -3×YFP transcriptional reporter containing the 224 bp immediately upstream of the *epsA* open reading frame and introduced it into strain PY79. Flow cytometry was used to quantify gene expression at the single-cell level. When the cells were grown on minimal medium, the *eps* reporter was expressed in a bimodal manner (Fig. 4A). In a small subpopulation of cells, YFP was expressed at levels approximately 15 times higher than the background level (the ON cell population), whereas the majority of the cells did not express significant levels of YFP (the OFF cell population). The fraction of ON cells increased over time, reaching about 20% of the total population several hours after the onset of the stationary phase (Fig. 4A). Integration of the $P_{hs-rapP}$ construct into PY79 and its induction in the presence of 10 μM IPTG did not significantly change the mean fluorescence levels of either the ON or OFF population. Instead, the fraction of the ON population was kept at a constant basal level of less than 10% of the population, without the significant increase in the fraction of ON cells observed in the stationary phase in strain PY79 (Fig. 4B).

Since other RapP functions seem to be dependent on ComA (Fig. 3), it is possible that ComA has a role in the observed dependence of the *eps* operon expression profile on RapP. Indeed, a *comA* deletion reduced the fraction of the *eps* ON population to that observed in the RapP-expressing strain (Fig. 4C). Induction of RapP using the $P_{hs-rapP}$ in the *comA* null mutant background did not further reduce the frequency of ON cells (Fig. 4C). These results demonstrate that bistability of the *eps* operon is modulated by ComA and that its interaction with RapP contributes to *eps* expression. These results do not rule out that RapP also affects *eps* expression through Spo0A.

The effect of RapP on sporulation is ComA independent. RapP has also been shown to affect genes directly targeted by Spo0A~P (29). We therefore examined the involvement of RapP and ComA in sporulation (Table 3). We found that ComA had little effect on sporulation levels of strain PY79. On the other hand, sporulation levels were markedly reduced when $P_{hs-rapP}$ was introduced into strain PY79 or the PY79 *comA* null mutant strain, clearly demonstrating a ComA-independent role for RapP, in accordance with the direct interaction observed between RapP and Spo0F (29). We note that in order for *rapP* to have an effect on sporulation, much higher levels of IPTG (1 mM) were required




FIG 4 Dependence of *eps* expression on *comA* and *rapP* mutations. (A and B) The distribution of expression levels of YFP driven by the *eps* promoter as a function of time in strain AES1819 (PY79 $P_{eps-3\times YFP}$) (A) and strain AES1820 ($P_{rapP-rapP-phrP}$ $P_{eps-3\times YFP}$) (B). Note the difference between strains in the fraction of high-YFP-expressing cells (ON population) and how expression changes over time. (C) Shown are the fractions of the ON cells for strains that express the $P_{eps-3\times YFP}$ reporter in the following genetic backgrounds: AES1819 (PY79 wild-type), AES1820 ($P_{rapP-rapP-phrP}$), AES1827 ($\Delta comA$), and AES1828 ($\Delta comA$ $P_{hs-rapP}$). Inducible constructs were induced with 10 μM IPTG.

than those used to observe the effects of RapP on *eps* and *srfA* gene expression.

The *rapP* allele of strain 3610 carries a substitution in a highly conserved residue whose reversion reconstitutes interaction with *phrP*. It has previously been reported that repression by RapP is not alleviated by expression of the *phrP* gene or by exogenous addition of the candidate pentapeptide or hexapeptide signals (29). This behavior is unique to the RapP-*phrP* system; all other characterized Rap proteins which have an adjoining *phr* gene in the same operon are affected by the corresponding signaling peptide (9). The *PhrP* independence of RapP was retained when *rapP* and *phrP* were introduced into strain PY79. Moreover,

overexpression of *phrP* had no effect on the RapP-dependent repression of *srfA* in strain PY79 (Fig. 5B).

Highly similar *rapP* homologues are present in plasmid pLS32 and in the chromosomal genomes of *B. subtilis* subsp. *spizizenii* TU-B-10, *B. vallismortis* strain DV1-F-3, and *B. atrophaeus* strain 1942. By aligning these proteins, we noticed that the *rapP* allele of pBS32 in strain 3610 (here, *rapP*³⁶¹⁰) has an asparagine-to-threonine substitution at position 236, which results from an A-to-C substitution in position 707 of the gene (Fig. 5A). Sequence alignment of all other Rap proteins of strain 3610 show that they contain asparagine in the homologous position (Fig. 5A). Further alignment of 107 different Rap proteins from *B. subtilis* isolates

TABLE 3 The effect of *comA* and *rapP* on sporulation

Strain	Relevant genotype	No. of viable cells ^a	No. of heat-resistant cells ^a	Sporulation efficiency (%) ^a	Mean sporulation efficiency (%) ^b
AES101	PY79	5×10^8	2×10^8	40	36 ± 8
AES1403	PY79 $\Delta comA$	2.6×10^8	2.03×10^8	78	51 ± 12
AES1444	PY79 $P_{hs-rapP}$	1.61×10^8	6.2×10^5	0.39	0.39 ± 0.06
AES1503	PY79 $\Delta comA$ $P_{hs-rapP}$	1.04×10^8	3.47×10^5	0.33	0.32 ± 0.05

^a A single colony was inoculate into 1 ml of Difco sporulation medium (with 1 mM IPTG, if needed) and grown for 24 h. Serial dilutions were plated onto nonselective LB agar plates before and after the cells were heating to 80°C for 20 min. The results of a single experiment are shown, and values are representative.

^b Mean and standard error of sporulation efficiency for each strain. Statistics are based on 3 to 6 biological replicates for each strain. The difference between strains AES101 and AES1403 is not significant ($P = 0.36$, two-sample *t* test). The difference between strains AES1444 and AES1503 is not significant ($P = 0.44$, two-sample *t* test). The difference between strains AES1403 and AES1503 is significant ($P = 0.01$, two-sample *t* test).




FIG 5 $rapP^{3610}$ codes for an N236T substitution mutation compared to the consensus, which renders it insensitive to the PhrP peptide. (A) Sequence alignment of amino acids 226 to 250 from RapP³⁶¹⁰ with the sequences of other RapP homologues and with other Rap proteins found in strain 3610. Asparagine residue 236 is conserved in all Rap proteins except for the product of $rapP^{3610}$, where it is replaced with threonine. Residue 236 of RapP is shown in boldface, and the aligned column is boxed for emphasis. (B) The addition of an IPTG-inducible $phrP$ gene suppresses the effect of $rapP^{T236N}$ but not of $rapP^{3610}$ on P_{srfA} -3×YFP expression. Shown are YFP expression levels of a P_{srfA} -3×YFP reporter in strain PY79 with different backgrounds, where each genotype was measured with (+) or without (-) a P_{hs} - $phrP$ construct. Genotypes are as follows: wild-type PY79 (AES1334), P_{hs} - $phrP$ (AES1477), P_{rapP} - $rapP^{3610}$ (AES1380), P_{rapP} - $rapP^{3610}$ P_{hs} - $phrP$ (AES1478), P_{rapP} - $rapP^{T236N}$ (AES1678), and P_{rapP} - $rapP^{T236N}$ P_{hs} - $phrP$ (AES1709). Expression was measured at an OD₆₀₀ of 1.5, and IPTG was added at 10 μM when needed. (C) P_{srfA} -3×YFP expression was monitored in a P_{rapP} - $rapP^{T236N}$ (AES1678) background as a function of the concentration of the externally added peptides. Three peptides were tested for their ability to repress $rapP^{T236N}$ activity: the putative signaling peptides of PhrP (DRAAT or ADRAAT) and the hexapeptide signal of PhrH (TDRNTT).

showed that asparagine is conserved in all of them (see Fig. S2 in the supplemental material). The threonine substitution is therefore a unique variant. Structurally, the homologous asparagines in RapF and RapJ have been shown to strongly interact with the backbone of the signaling peptide (11, 12). More generally, asparagine residues typically mediate interaction with peptide backbone in other TPR domains (42).

In order to determine whether the N236T substitution rendered the RapP³⁶¹⁰ allele insensitive to PhrP, we used *in vitro* mutagenesis to introduce a threonine-to-asparagine substitution at position 236 of the P_{rapP} - $rapP^{3610}$ construct. This allele, which we designate $rapP^{T236N}$, was introduced into strain PY79 containing a P_{srfA} -3×YFP reporter. This led to the same level of repression of P_{srfA} -3×YFP expression as did the introduction of the $rapP^{3610}$

allele (Fig. 5B), indicating that this change did not affect the activity of RapP in the absence of the $phrP$ gene product. To determine whether introduction of $phrP$ could derepress the RapP^{T236N} allele but not the RapP³⁶¹⁰ allele, we introduced the $phrP$ gene, driven by the P_{hs} inducible promoter, into the different strains. The addition of this construct to the $rapP^{3610}$ - $phrP$ strain had no effect on P_{srfA} -3×YFP expression, irrespective of the level of IPTG used. On the other hand, the addition of the P_{hs} - $phrP$ construct to a strain containing $rapP^{T236N}$ restored P_{srfA} -3×YFP expression to its wild-type levels, demonstrating full suppression of RapP^{T236N} activity (Fig. 5B). This derepression was also observed without the addition of IPTG, indicating that the leakiness of the hyperspank promoter produces a sufficient amount of signal to inhibit RapP^{N236T} activity.




FIG 6 Replacement of *rapP*³⁶¹⁰ by *rapP*^{T236N} eliminates the phenotypic effects of the pBS32 plasmid on ComA activity and biofilm formation. (A) Biofilm formation by the 3610 plasmid-free strain (DS2569), 3610 *rapP*^{T236N}-*phrP* strain (AES1707), and strain 3610 (*rapP*³⁶¹⁰-*phrP*, AES1109). (B) YFP expression levels of *P*_{srfA}-3×YFP as a function of optical density during growth in SMM for the following backgrounds: 3610 plasmid-free strain (AES1605), 3610 *rapP*^{T236N}-*phrP* strain (AES1873), and strain 3610 (*rapP*³⁶¹⁰-*phrP*, AES1336).

The Phr signaling peptides are penta- or hexapeptides often derived from the C terminus of the Phr polypeptide (9). The candidate PhrP signaling peptides are therefore DRAAT and ADR AAT. To quantify the activity of these peptides, we grew PY79 strains containing the *P*_{srfA}-3×YFP reporter and either *P*_{hs}-*rapP*³⁶¹⁰ or *P*_{hs}-*rapP*^{T236N} in various concentrations of the two peptides (Fig. 5C). YFP expression was restored to wild-type levels upon addition of a high concentration of either peptide to the strain carrying the *rapP*^{T236N} allele, but for any given concentration, the hexapeptide showed higher activation than the penta-peptide. A significant increase in YFP expression levels was observed at peptide concentrations of 300 nM or higher, which is similar to the concentration that was reported for PhrG (19) but significantly higher than that of the PhrC signal, competence- and sporulation-stimulating factor (CSF) (6). No effect was observed by addition of either peptide to the *rapP*³⁶¹⁰ strain or the addition of the PhrH hexapeptide to either strain (Fig. 5C).

Biofilm and ComA phenotypes associated with the pBS32 plasmid are abolished in the *rapP*^{T236N} background. As PhrP inhibits RapP at a high peptide density, we wondered whether the replacement of *rapP*³⁶¹⁰ with *rapP*^{T236N} would render both biofilm formation and ComA activity independent of the plasmid pBS32. To this end, we compared the biofilm phenotypes of three strains: (i) strain DS2569, a plasmid-free version of strain 3610 (25, 26); (ii) strain AES1707 (3610 *rapP*^{T236N}-*phrP*), where the *rapP*-*phrP* cassette was deleted from the pBS32 plasmid and the substituted *rapP*^{T236N}-*phrP* cassette was inserted into the chromosomal *sacA* locus; and (iii) strain 3610. As shown in Fig. 6A, when the plasmid-free strain was plated on MSgg agar, its biofilm phenotype

was highly similar to that of strain 3610 *rapP*^{T236N}-*phrP* but markedly different from that of strain 3610.

We expect that the introduction of *rapP*^{T236N} will also cancel the effect of RapP on ComA activity. To this end, a *P*_{srfA}-3×YFP reporter was introduced into the three strains described above in order to monitor ComA activity. We found that YFP expression levels were identical in the plasmid-free strain and the 3610 *rapP*^{T236N}-*phrP* strain. Both strains showed expression levels which were 6 times higher than the level in strain 3610 (Fig. 6B). It should be noted that the *P*_{srfA} expression profile in the plasmid-free strain was still markedly different from *P*_{srfA} expression in the lab strain, PY79 (see Fig. S3 in the supplemental material), presumably due to additional mutations that distinguish the two strains (23, 25).

DISCUSSION

The Rap-Phr system is prevalent in the *B. subtilis* and *Bacillus cereus* groups of *Bacillus* species. All characterized Rap-Phr pairs form quorum-sensing systems, with the Phr peptide inhibiting the function of its cognate Rap. In this regard, RapP represents a unique case in which the association between Rap and Phr does not occur. Here, we show that this unique behavior is due to an atypical substitution in a highly conserved residue within the TPR domain of RapP. The full conservation of the asparagine residue may suggest that the atypical mutation arose during the early stages of domestication of the strain. Since strain 3610 is the earliest known ancestor of a domesticated strain such as *B. subtilis* 168, it is impossible to validate the hypothesis.

The typical organization of the Rap-Phr pairs implies that the

effect of Rap proteins is most pronounced at low or intermediate cell densities. At higher cell densities, and especially under conditions where a sufficient amount of cells activate the Spo0A pathway, the effect of the Rap protein is suppressed by the Phr peptide. Indeed, deletion of Rap genes usually results in a modest effect on phenotype (16), especially during the beginning of the stationary phase (43, 44). The RapP³⁶¹⁰ allele does not obey this rule since it is not counteracted by PhrP, and therefore its deletion has a strong effect on biofilm formation and ComA activity. We therefore propose that the biofilm phenotypes of the RapP^{T236N} allele and of the plasmid-free strain are more typical than the biofilm phenotype of strain 3610.

Combining our genetic analysis with previous analysis of RapP (29) suggests that RapP acts on several targets. It was previously reported that RapP is involved in dephosphorylation of Spo0F (29). These biochemical results are in line with our finding that expression of RapP strongly affected sporulation efficiency (Table 3). On the other hand, our genetic analyses (Fig. 3 and 4) indicate that the control of ComA activity by RapP is partially independent of Spo0F. While it is tempting to speculate that RapP directly interacts with ComA, previous attempts to observe such interaction were unsuccessful (29). The identity of the second target of RapP, therefore, remains to be discovered.

We have also identified a positive regulatory effect of the QS master regulator, ComA, on the expression of the exopolysaccharide (*eps*) operon. This effect has been reported previously based on the analysis of microarray experiments (4). Using single-cell measurements, we find that ComA modulates the fraction of cells expressing the *eps* operon and not the level of expression. This indicates that ComA modulates the bistable positive feedback that governs the expression of biofilm-related genes (45). It was previously reported that ComA controls the Spo0A phosphorelay through the production of surfactin and the latter's effect on the phosphorelay kinase KinC (46). In addition, ComA has been shown to regulate biofilm formation through the activation of *degQ* (47). Strain PY79 does not produce surfactin and has a hypomorphic allele of the *degQ* promoter, implying that both of these pathways probably do not explain our results. Importantly, we find that ComA is a weak modulator of *eps* expression (the deletion leads only to a factor of 2 effect in the frequency of *eps* ON cells). We would therefore expect this effect to vary with environment and genotype, reconciling conflicting reports about the importance of this locus to biofilm formation (38, 48). It is important to note that RapP repression of the *eps* operon is probably mediated also by Spo0A.

Finally, many Rap-Phr systems have been shown to be encoded by mobile genetic elements (37), in a fashion similar to the RapP-PhrP system. In the mobile integrative and conjugative element ICEBs1, RapI-PhrI-mediated QS was shown to facilitate horizontal gene transfer and to dephosphorylate Spo0F. In addition, Rap60 encoded on the plasmid pTA1060 has been shown to regulate degradative enzyme production, possibly by dephosphorylation of Spo0F~P (49). The sporadic occurrence of plasmid pBS32 within the *B. subtilis* lineage implies that it is horizontally transferred, but the mechanism is unknown; therefore, it is yet unclear whether the RapP-PhrP system has an impact on the plasmid's horizontal transfer. The possible functions of Rap-Phr systems in mobile genetic elements and how they influence the spread and symbiosis of these elements with their host remain important open questions, the answers to which are likely to shed new light on the function of this broad and diverse family of QS systems.

ACKNOWLEDGMENTS

We thank Daniel Kearns for strains and discussions and David Gutnick, Dave Dubnau, Matthew Neiditch, Gil Segal, Naama Geva-Zatorsky, and members of the Eldar lab for discussions.

This work was supported by funding from the Human Frontier Science Program grant CDA00015/2010-C (A.E.), Marie Curie International Reintegration Grant 268304 (S.O.B.), and European Research Council grant 281301 (A.E. and S.P.).

We declare we have no conflicts of interest in the publication of this paper.

REFERENCES

- Kleerebezem M, Quadri LE, Kuipers OP, De Vos WM. 1997. Quorum sensing by peptide pheromones and two-component signal-transduction systems in Gram-positive bacteria. *Mol Microbiol* 24:895–904. <http://dx.doi.org/10.1046/j.1365-2958.1997.4251782.x>.
- Waters CM, Bassler BL. 2005. Quorum sensing: cell-to-cell communication in bacteria. *Annu Rev Cell Dev Biol* 21:319–346. <http://dx.doi.org/10.1146/annurev.cellbio.21.012704.131001>.
- Lyon GJ, Novick RP. 2004. Peptide signaling in *Staphylococcus aureus* and other Gram-positive bacteria. *Peptides* 25:1389–1403. <http://dx.doi.org/10.1016/j.peptides.2003.11.026>.
- Comella N, Grossman AD. 2005. Conservation of genes and processes controlled by the quorum response in bacteria: characterization of genes controlled by the quorum-sensing transcription factor ComA in *Bacillus subtilis*. *Mol Microbiol* 57:1159–1174. <http://dx.doi.org/10.1111/j.1365-2958.2005.04749.x>.
- Dunny GM. 2007. The peptide pheromone-inducible conjugation system of *Enterococcus faecalis* plasmid pCF10: cell-cell signalling, gene transfer, complexity and evolution. *Philos Trans R Soc Lond B Biol Sci* 362:1185–1193. <http://dx.doi.org/10.1098/rstb.2007.2043>.
- Lazazzera BA, Solomon JM, Grossman AD. 1997. An exported peptide functions intracellularly to contribute to cell density signaling in *B. subtilis*. *Cell* 89:917–925. [http://dx.doi.org/10.1016/S0092-8674\(00\)80277-9](http://dx.doi.org/10.1016/S0092-8674(00)80277-9).
- Li Y-H, Tang N, Aspiras MB, Lau PC, Lee JH, Ellen RP, Cvitkovich DG. 2002. A quorum-sensing signaling system essential for genetic competence in *Streptococcus mutans* is involved in biofilm formation. *J Bacteriol* 184:2699–2708. <http://dx.doi.org/10.1128/JB.184.10.2699-2708.2002>.
- Perego M, Hoch JA. 1996. Cell-cell communication regulates the effects of protein aspartate phosphatases on the phosphorelay controlling development in *Bacillus subtilis*. *Proc Natl Acad Sci U S A* 93:1549–1553. <http://dx.doi.org/10.1073/pnas.93.4.1549>.
- Lazazzera BA, Grossman AD. 1998. The ins and outs of peptide signaling. *Trends Microbiol* 6:288–294. [http://dx.doi.org/10.1016/S0966-842X\(98\)01313-4](http://dx.doi.org/10.1016/S0966-842X(98)01313-4).
- Perego M. 2013. Forty Years in the making: understanding the molecular mechanism of peptide regulation in bacterial development. *PLoS Biol* 11:e1001516. <http://dx.doi.org/10.1371/journal.pbio.1001516>.
- Parashar V, Jeffrey PD, Neiditch MB. 2013. Conformational change-induced repeat domain expansion regulates Rap phosphatase quorum-sensing signal receptors. *PLoS Biol* 11:e1001512. <http://dx.doi.org/10.1371/journal.pbio.1001512>.
- Gallejo del Sol F, Marina A. 2013. Structural basis of Rap phosphatase inhibition by Phr peptides. *PLoS Biol* 11:e1001511. <http://dx.doi.org/10.1371/journal.pbio.1001511>.
- Vlamakis H, Chai Y, Beaugerard P, Losick R, Kolter R. 2013. Sticking together: building a biofilm the *Bacillus subtilis* way. *Nat Rev Microbiol* 11:157–168. <http://dx.doi.org/10.1038/nrmicro2960>.
- Molle V, Fujita M, Jensen ST, Eichenberger P, González-Pastor JE, Liu JS, Losick R. 2003. The Spo0A regulon of *Bacillus subtilis*. *Mol Microbiol* 50:1683–1701. <http://dx.doi.org/10.1046/j.1365-2958.2003.03818.x>.
- McQuade RS, Comella N, Grossman AD. 2001. Control of a family of phosphatase regulatory genes (*phr*) by the alternate sigma factor sigma-H of *Bacillus subtilis*. *J Bacteriol* 183:4905–4909. <http://dx.doi.org/10.1128/JB.183.16.4905-4909.2001>.
- Auchtung JM, Lee CA, Grossman AD. 2006. Modulation of the ComA-dependent quorum response in *Bacillus subtilis* by multiple Rap proteins and Phr peptides. *J Bacteriol* 188:5273–5285. <http://dx.doi.org/10.1128/JB.00300-06>.
- Ogura M, Fujita Y. 2007. *Bacillus subtilis rapD*, a direct target of tran-

- scription repression by RghR, negatively regulates *srfA* expression. FEMS Microbiol Lett 268:73–80. <http://dx.doi.org/10.1111/j.1574-6968.2006.00559.x>.
18. Lazazzera BA, Kurtser IG, McQuade RS, Grossman AD. 1999. An autoregulatory circuit affecting peptide signaling in *Bacillus subtilis*. J Bacteriol 181:5193–5200.
 19. Ogura M, Shimane K, Asai K, Ogasawara N, Tanaka T. 2003. Binding of response regulator DegU to the *aprE* promoter is inhibited by RapG, which is counteracted by extracellular PhrG in *Bacillus subtilis*. Mol Microbiol 49: 1685–1697. <http://dx.doi.org/10.1046/j.1365-2958.2003.03665.x>.
 20. Murray EJ, Kiley TB, Stanley-Wall NR. 2009. A pivotal role for the response regulator DegU in controlling multicellular behaviour. Microbiology 155:1–8. <http://dx.doi.org/10.1099/mic.0.023903-0>.
 21. Singh PK, Ramachandran G, Ramos-Ruiz R, Peiró-Pastor R, Abia D, Wu LJ, Meijer WJ. 2013. Mobility of the native *Bacillus subtilis* conjugative plasmid pLS20 is regulated by intercellular signaling. PLoS Genet 9:e1003892. <http://dx.doi.org/10.1371/journal.pgen.1003892>.
 22. Branda SS, González-Pastor JE, Ben-Yehuda S, Losick R, Kolter R. 2001. Fruiting body formation by *Bacillus subtilis*. Proc Natl Acad Sci U S A 98:11621–11626. <http://dx.doi.org/10.1073/pnas.191384198>.
 23. Zeigler DR, Prágai Z, Rodriguez S, Chevreux B, Muffler A, Albert T, Bai R, Wyss M, Perkins JB. 2008. The origins of 168, W23, and other *Bacillus subtilis* legacy strains. J Bacteriol 190:6983–6995. <http://dx.doi.org/10.1128/JB.00722-08>.
 24. Aguilar C, Vlamakis H, Losick R, Kolter R. 2007. Thinking about *Bacillus subtilis* as a multicellular organism. Curr Opin Microbiol 10:638–643. <http://dx.doi.org/10.1016/j.mib.2007.09.006>.
 25. McLoon AL, Guttenplan SB, Kearns DB, Kolter R, Losick R. 2011. Tracing the domestication of a biofilm-forming bacterium. J Bacteriol 193:2027–2034. <http://dx.doi.org/10.1128/JB.01542-10>.
 26. Konkol MA, Blair KM, Kearns DB. 2013. Plasmid-encoded ComI inhibits competence in the ancestral strain of *Bacillus subtilis*. J Bacteriol 195: 4085–4093. <http://dx.doi.org/10.1128/JB.00696-13>.
 27. Durrett R, Miras M, Mirouze N, Narechania A, Mandic-Mulec I, Dubnau D. 2013. Genome sequence of the *Bacillus subtilis* biofilm-forming transformable strain PS216. Genome Announc 1(3):e00288–13. <http://dx.doi.org/10.1128/genomeA.00288-13>.
 28. Tanaka T. 2010. Functional analysis of the stability determinant AlfB of pBET131, a miniplasmid derivative of *Bacillus subtilis* (*natto*) plasmid pLS32. J Bacteriol 192:1221–1230. <http://dx.doi.org/10.1128/JB.01312-09>.
 29. Parashar V, Konkol MA, Kearns DB, Neiditch MB. 2013. A plasmid-encoded phosphatase regulates *Bacillus subtilis* biofilm architecture, sporulation, and genetic competence. J Bacteriol 195:2437–2448. <http://dx.doi.org/10.1128/JB.02030-12>.
 30. Chu F, Kearns DB, McLoon A, Chai Y, Kolter R, Losick R. 2008. A novel regulatory protein governing biofilm formation in *Bacillus subtilis*. Mol Microbiol 68:1117–1127. <http://dx.doi.org/10.1111/j.1365-2958.2008.06201.x>.
 31. Smits WK, Bongiorno C, Veening JW, Hamoen LW, Kuipers OP, Perego M. 2007. Temporal separation of distinct differentiation pathways by a dual specificity Rap-Phr system in *Bacillus subtilis*. Mol Microbiol 65:103–120. <http://dx.doi.org/10.1111/j.1365-2958.2007.05776.x>.
 32. Wach A. 1996. PCR-synthesis of marker cassettes with long flanking homology regions for gene disruptions in *S. cerevisiae*. Yeast 12:259–265. [http://dx.doi.org/10.1002/\(SICI\)1097-0061\(19960315\)12:3<259::AID-YEA901>3.0.CO;2-C](http://dx.doi.org/10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C).
 33. Britton RA, Eichenberger P, Gonzalez-Pastor JE, Fawcett P, Monson R, Losick R, Grossman AD. 2002. Genome-wide analysis of the stationary-phase sigma factor (sigma-H) regulon of *Bacillus subtilis*. J Bacteriol 184: 4881–4890. <http://dx.doi.org/10.1128/JB.184.17.4881-4890.2002>.
 34. Eldar A, Chary VK, Xenopoulos P, Fontes ME, Losón OC, Dworkin J, Piggot PJ, Elowitz MB. 2009. Partial penetrance facilitates developmental evolution in bacteria. Nature 460:510–514. <http://dx.doi.org/10.1038/nature08150>.
 35. Harwood CR, Cutting SM (ed). 1990. Molecular biological methods for *Bacillus*. Wiley, New York, NY.
 36. Yasbin RE, Young FE. 1974. Transduction in *Bacillus subtilis* by bacteriophage SPP1. J Virol 14:1343–1348.
 37. Auchtung JM, Lee CA, Monson RE, Lehman AP, Grossman AD. 2005. Regulation of a *Bacillus subtilis* mobile genetic element by intercellular signaling and the global DNA damage response. Proc Natl Acad Sci U S A 102:12554–12559. <http://dx.doi.org/10.1073/pnas.0505835102>.
 38. López D, Vlamakis H, Losick R, Kolter R. 2009. Paracrine signaling in a bacterium. Genes Dev 23:1631–1638. <http://dx.doi.org/10.1101/gad.1813709>.
 39. Dworkin J, Losick R. 2001. Differential gene expression governed by chromosomal spatial asymmetry. Cell 107:339–346. [http://dx.doi.org/10.1016/S0092-8674\(01\)00528-1](http://dx.doi.org/10.1016/S0092-8674(01)00528-1).
 40. Frandsen N, Barák I, Karmazyn-Campelli C, Stragier P. 1999. Transient gene asymmetry during sporulation and establishment of cell specificity in *Bacillus subtilis*. Genes Dev 13:394–399. <http://dx.doi.org/10.1101/gad.13.4.394>.
 41. Hahn J, Dubnau D. 1991. Growth stage signal transduction and the requirements for *srfA* induction in development of competence. J Bacteriol 173:7275–7282.
 42. D'Andrea LD, Regan L. 2003. TPR proteins: the versatile helix. Trends Biochem Sci 28:655–662. <http://dx.doi.org/10.1016/j.tibs.2003.10.007>.
 43. Veening JW, Hamoen LW, Kuipers OP. 2005. Phosphatases modulate the bistable sporulation gene expression pattern in *Bacillus subtilis*. Mol Microbiol 56:1481–1494. <http://dx.doi.org/10.1111/j.1365-2958.2005.04659.x>.
 44. Serra CR, Earl AM, Barbosa TM, Kolter R, Henriques AO. 15 September 2014. Sporulation during growth in a gut isolate of *Bacillus subtilis*. J Bacteriol <http://dx.doi.org/10.1128/JB.01993-14>.
 45. Chai Y, Norman T, Kolter R, Losick R. 2010. An epigenetic switch governing daughter cell separation in *Bacillus subtilis*. Genes Dev 24:754–765. <http://dx.doi.org/10.1101/gad.1915010>.
 46. López D, Fischbach MA, Chu F, Losick R, Kolter R. 2009. Structurally diverse natural products that cause potassium leakage trigger multicellularity in *Bacillus subtilis*. Proc Natl Acad Sci U S A 106:280–285. <http://dx.doi.org/10.1073/pnas.0810940106>.
 47. Stanley NR, Lazazzera BA. 2005. Defining the genetic differences between wild and domestic strains of *Bacillus subtilis* that affect poly- γ -dl-glutamic acid production and biofilm formation. Mol Microbiol 57:1143–1158. <http://dx.doi.org/10.1111/j.1365-2958.2005.04746.x>.
 48. Hamon MA, Lazazzera BA. 2001. The sporulation transcription factor Spo0A is required for biofilm development in *Bacillus subtilis*. Mol Microbiol 42:1199–1209. <http://dx.doi.org/10.1046/j.1365-2958.2001.02709.x>.
 49. Koetje EJ, Hajdo-Milasinovic A, Kiewiet R, Bron S, Tjalsma H. 2003. A plasmid-borne Rap-Phr system of *Bacillus subtilis* can mediate cell-density controlled production of extracellular proteases. Microbiology 149:19–28. <http://dx.doi.org/10.1099/mic.0.25737-0>.
 50. Silvaggi JM, Perkins JB, Losick R. 2006. Genes for small, noncoding RNAs under sporulation control in *Bacillus subtilis*. J Bacteriol 188:532–541. <http://dx.doi.org/10.1128/JB.188.2.532-541.2006>.